Ildong Pharmaceutical Receives Approval for Changes to Oral COVID-19 Treatment Clinical Trial Plan
[Asia Economy Reporter Kim Hyung-min] Ildong Pharmaceutical announced on the 24th that the Ministry of Food and Drug Safety (MFDS) has approved the change in the Phase 2 and 3 clinical trial plans for S-217622 (product name Zokova), an oral COVID-19 treatment candidate.
Earlier, Ildong Pharmaceutical disclosed on the 11th that it had applied to the MFDS for changes to the Phase 2 and 3 clinical trial plans for S-217622. This was explained as being due to the change in the clinical trial protocol by Shionogi of Japan.
Hot Picks Today
!["Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"](https://cwcontent.asiae.co.kr/asiaresize/93/2026051507261063923_1778797570.png)
"Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- "Total Blockout"... Trump Team Tosses All 'Items Received from China' in Trash Before Boarding Private Jet
- Experts Already Watching Closely..."Target Price Set at 970,000 Won" Only Upward Momentum Remains [Weekend Money]
S-217622 works by inhibiting the binding of the protease (Mpro), a protein involved in the 'replication' process by which the virus proliferates. Ildong Pharmaceutical signed a joint development agreement with Shionogi Pharmaceutical last November and has been conducting domestic clinical trials since January.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
